Literature DB >> 25872803

Force spectroscopy of multivalent binding of riboflavin-conjugated dendrimers to riboflavin binding protein.

Abigail N Leistra, Jong Hyun Han, Shengzhuang Tang1, Bradford G Orr1,2, Mark M Banaszak Holl1,3,4, Seok Ki Choi1,5, Kumar Sinniah.   

Abstract

Putative riboflavin receptors are considered as biomarkers due to their overexpression in breast and prostate cancers. Hence, these receptors can be potentially exploited for use in targeted drug delivery systems where dendrimer nanoparticles with multivalent ligand attachments can lead to greater specificity in cellular interactions. In this study, the single molecule force spectroscopy technique was used to assess the physical strength of multivalent interactions by employing a riboflavin (RF)-conjugated generation 5 PAMAM dendrimer G5(RF)n nanoparticle. By varying the average RF ligand valency (n = 0, 3, 5), the rupture force was measured between G5(RF)n and the riboflavin binding protein (RFBP). The rupture force increased when the valency of RF increased. We observed at the higher valency (n = 5) three binding events that increased in rupture force with increasing loading rate. Assuming a single energy barrier, the Bell-Evans model was used to determine the kinetic off-rate and barrier width for all binding interactions. The analysis of our results appears to indicate that multivalent interactions are resulting in changes to rupture force and kinetic off-rates.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25872803     DOI: 10.1021/acs.jpcb.5b01028

Source DB:  PubMed          Journal:  J Phys Chem B        ISSN: 1520-5207            Impact factor:   2.991


  3 in total

1.  Characterization of Folic Acid and Poly(amidoamine) Dendrimer Interactions with Folate Binding Protein: A Force-Pulling Study.

Authors:  Pascale R Leroueil; Stassi DiMaggio; Abigail N Leistra; Craig D Blanchette; Christine Orme; Kumar Sinniah; Bradford G Orr; Mark M Banaszak Holl
Journal:  J Phys Chem B       Date:  2015-08-14       Impact factor: 2.991

2.  An Avidity-Based PD-L1 Antagonist Using Nanoparticle-Antibody Conjugates for Enhanced Immunotherapy.

Authors:  Jiyoon Bu; Ashita Nair; Mari Iida; Woo-Jin Jeong; Michael J Poellmann; Kara Mudd; Luke J Kubiatowicz; Elizabeth W Liu; Deric L Wheeler; Seungpyo Hong
Journal:  Nano Lett       Date:  2020-06-11       Impact factor: 11.189

Review 3.  Riboflavin-Targeted Drug Delivery.

Authors:  Milita Darguzyte; Natascha Drude; Twan Lammers; Fabian Kiessling
Journal:  Cancers (Basel)       Date:  2020-01-27       Impact factor: 6.639

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.